Evidence map›Paper›PMID 41220063›Full record

ArticleAnnals of surgery2025

A Randomized, Single-Center, Superiority Trial of Radioactive Seed Localization Versus Wire Localization for Malignant Breast Disease.

Lejla Hadzikadic-Gusic, Jessica Bilz, Danielle Boselli, James Symanowski, Michelle Wallander, Laura Danile, Amy Sobel, Chad Livasy, Terry Sarantou, Amy Voci and 12 more

Abstract readEquivalence Trial
In one paragraph

Article in Annals of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Lejla Hadzikadic-GusicDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Jessica BilzDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Danielle BoselliDepartment of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC.
James SymanowskiDepartment of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Michelle WallanderClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Laura DanileCharlotte Radiology, Charlotte, NC.
Amy SobelCharlotte Radiology, Charlotte, NC.
Chad LivasyDepartment of Pathology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Terry SarantouDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Amy VociDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Deba SarmaDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Meghan ForsterDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Shirley ScottDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Whitney MitchelidesClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Sapana ShahClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Xhevahire BegicClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Cecilia FlynnDepartment of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Allison VerbylaDepartment of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Adilen CruzDepartment of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Almira SejdicClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Courtney SchepelClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Richard L WhiteDepartment of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCompare radioactive seed localization (RSL) and wire-guided localization (WL) for nonpalpable malignant breast disease.

backgroundWhile WL has been the most common approach for localization of nonpalpable breast tumors, other techniques such as RSL, intraoperative ultrasound, radioactive intraoperative occult lesion localization, hematoma localization, radar localization, and magnetic seed localization have been suggested as safe and efficacious alternatives. However, very few randomized controlled trials have compared these localization techniques.

methodsBetween July 2015 and January 2021, 400 women with nonpalpable malignant breast disease were randomized 1:1 to RSL or WL, stratified by the surgeon and invasive disease status. The primary outcome was initial resection negative margin rates. Secondary outcomes included time efficiencies, cost, and satisfaction.

resultsThere was no significant difference in negative margin rates between RSL and WL [RSL 0.80 (95% CI: 0.75-0.86) vs WL 0.85 (95% CI: 0.80-0.89); P=0.29]. RSL received better patient scores for anxiety [OR=2.62 (95% CI: 1.79-3.84); P<0.01], pain [OR=2.50 (95% CI: 1.69-3.71); P<0.01], and overall satisfaction [OR=3.24 (95% CI: 1.70-6.22); P<0.01] compared with WL. Radiologists and surgeons associated RSL with better convenience [OR=3.32 (95% CI: 1.65-6.69); P<0.01] and satisfaction of surgical procedure conduct [OR=1.67 (95% CI: 1.09-2.58); P=0.02]. Time in radiology did not differ [RSL mean (SD) 12.8±9.5 min vs. WL 11.4±6.0 min; P=0.18]. RSL incurred a $600 higher cost than WL.

conclusionsThe results of the largest randomized controlled trial in the United States support RSL as an acceptable alternative to WL in the treatment of nonpalpable malignant breast disease. While RSL was not superior to WL in achievement of negative margins, patients and providers reported improved satisfaction scores.

Indexed as

Breast NeoplasmsFiducial MarkersAdultAgedFemaleHumansMargins of ExcisionMastectomy, SegmentalMiddle AgedPatient Satisfactionbreast cancerbreast surgerycost-analysislocalizationradioactive seed localizationwire localization

Identifiers

PMID41220063
PMCPMC12594132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.